Biogen, Inc.
(NASDAQ : BIIB)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
MRNAModerna, Inc. 0.90%137.470.0%$901.93m
AMGNAmgen, Inc. 0.97%249.891.5%$836.96m
GILDGilead Sciences, Inc. 0.54%64.191.0%$544.98m
VRTXVertex Pharmaceuticals, Inc. 4.23%269.521.9%$481.48m
REGNRegeneron Pharmaceuticals, Inc. 3.43%683.792.6%$436.56m
ILMNIllumina, Inc. 0.91%245.713.3%$316.66m
NVAXNovavax, Inc. -1.75%52.4975.7%$302.15m
BIIBBiogen, Inc. 0.42%200.481.8%$241.04m
BNTXBioNTech SE 0.15%163.240.0%$226.75m
SNSSSunesis Pharmaceuticals, Inc. -0.47%2.100.7%$146.80m
EXASEXACT Sciences Corp. -1.93%52.1417.7%$144.24m
TECHBio-Techne Corp. -0.76%363.564.5%$100.03m
NKTXNkarta, Inc. 0.63%12.750.0%$99.89m
TXG10X Genomics, Inc. -1.47%49.430.0%$99.81m
BMRNBioMarin Pharmaceutical, Inc. 0.99%80.514.2%$99.38m

Company Profile

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. It offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of multiple sclerosis, SPINRAZA for the treatment of spinal muscular atrophy, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.